Skip to main content

Xtant Medical Holdings, Inc.

corporate_fare Company Profile

Xtant Medical Holdings, Inc.

XTNT·NYSE·Industrial Applications And Services·CIK 0001453593

Xtant Medical Holdings, Inc. is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. Xtant's biologics are also utilized in trauma, foot and ankle, sports medicine, total joint, along with several surgical repair and wound care applications. In the United States, Xtant promotes its products through independent distributors and stocking agents, supported by direct employees. It has an extensive sales channel of independent commissioned agents and stocking distributors in the United States representing some or all of its products. It also maintains a national accounts program to enable its agents to gain access to integrated delivery network (IDN) hospitals and through group purchasing organizations (GPOs). Xtant has biologics contracts with major GPOs, as well as extensive access to IDNs across the United States for both biologics and spine hardware systems. While its focus is the United States market, Xtant promotes and sells its products internationally through stocking distribution partners in Europe, Canada, Mexico, South America, and certain Pacific region countries. Xtant has focused primarily on four key growth initiatives: (1) introduce new products, including nanOss Strata™, an advanced synthetic bone graft designed to closely resemble natural bone; CollagenX™, a bovine collagen particulate product for surgical wound closure; OsteoFactor Pro TM, an allogenic growth factor solution; and Trivium™, a next-generation demineralized bone matrix, in addition to its 2024 introductions: Cortera ® Posterior Fixation System, viable bone matrix; OsteoVive ® Plus, and amniotic membrane allografts, SimpliGraft ™ and SimpliMax ™; (2) expand its distribution network; (3) penetrate adjacent markets; and (4) leverage its platform.

Xtant Medical Holdings, Inc. (NYSE:XTNT) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 2 items for XTNT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 2 most recent items scored 7 or higher, the top rating is 8/10, with 2 rated 8 or above. Recent SEC coverage for XTNT spans 10-Q, 8-K.

Recent high-impact activity:

  • Xtant 10-Q Details Cash Drain to $7.8M, Two Covenant Waivers and Unremediated Material Weakness
  • Xtant Medical Misses Guidance Again, Withdraws 2026 Outlook and Launches Board Strategic Review

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$133.93M
Net Income
$4.97M
Diluted EPS
$0.03
Op. Cash Flow
$12.55M
Free Cash Flow
$10.16M
Gross Profit
$84.27M
Operating Income
$7.28M
Cash & Equivalents
$17.05M
Total Debt
$14.53M
Debt / Equity
0.29×
Net Margin
3.7%
Shares Outstanding
140.04M sh
Source: 10-K · filed 2026-03-31 · accession 0001493152-26-013792

Short Interest & Short Volume

3.86 days to cover

FINRA reported short interest of 375,281 shares in XTNT as of the October 30, 2026 settlement, a 24.9% increase from the prior period — about 3.9 days to cover at its recent average daily volume. On November 20, 2026, 27.2% of XTNT volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)375,281 shares as of October 30, 2026
Change vs prior period▲ 24.9%
Days to cover3.86 at avg daily volume of 97,274
Daily short volume (FINRA facilities)27.2% of 100,881 shares on November 20, 2026
5-day average short volume30.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

$0.201 -4.29% today
52-week range · as of 2026-11-16 $0.201 – $0.84
Market cap
$29.49M
Volume
257.3K (1.3× avg)
3-mo avg 199.5K
Live data · 2026-11-22 01:28 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed XTNT - Latest Insights

XTNT
Nov 16, 2026, 7:15 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.2603
Real-time Price: $0.201 info
Change: -$0.0593 (-23%) info
Market Cap: $29.495M info
XTNT
Nov 16, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.2603
Real-time Price: $0.201 info
Change: -$0.0593 (-23%) info
Market Cap: $29.495M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets